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The metabolism of inorganic arsenic (iAs) in
humans involves two types of chemical
reactions, the reduction of pentavalent
arsenicals to trivalency and the oxidative
methylation of trivalent arsenicals to yield
methylated pentavalent metabolites (1)
(Figure 1). Glutathione (GSH) has been
shown to reduce pentavalent arsenicals (arse-
nate iAsV), methylarsonic acid (MAsV), and
dimethylarsinic acid (DMAsV) in aqueous
solutions (2,3). AsV reductases may enzy-
matically reduce these arsenicals in mam-
malian tissues (4,5). Methylation of
trivalent arsenicals [arsenite (iAsIII) and
methylarsonous acid (MAsIII)] is catalyzed
by AsIII-methyltransferases that use
S-adenosylmethionine (AdoMet) as the
methyl group donor (6,7). Because MAsV
and DMAsV are not toxic in acute lethality
assays, methylation of iAs has long been
considered a detoxification mechanism.
However, methylated arsenicals that are
chemically consistent with trivalent methyl-
ated metabolites, MAsIII and dimethylarsi-
nous acid (DMAsIII), have been shown to be
more potent enzyme inhibitors and cyto-
toxins than either iAsV or iAsIII (8).
Diiodomethylarsine (MAsIIII2) and methyl-
arsine oxide (MAsIIIO) are potent inhibitors
of glutathione disulfide (GSSG) reductase
(9), pyruvate dehydrogenase (10), and espe-
cially thioredoxin reductase (11). MAsIIIO
and MAsIIII2 are also far more toxic than
iAsIII for various types of mammalian cells
(12–14). DMAsIII derivatives [iododimethy-
larsine (DMAsIIII) and dimethylarsinous-
glutathione (DMAsIIIGS)] are at least as
cytotoxic as iAsIII for most cell types examined.
Notably, exposures to low concentrations of
either MAsIIIO or DMAsIIII induce cell
proliferation and production of growth-
promoting cytokines in normal human ker-
atinocytes (NHEK) (15). Unlike iAsIII and
iAsV, MAsIIIO and DMAsIIII react directly
with DNA, nicking naked DNA in vitro and
damaging nuclear DNA in intact human
leukocytes (16). Evidence for the formation
of methylated trivalent arsenicals in the
course of the metabolism of iAs in humans
has been obtained using optimized analytical
techniques (17,18). MAsIII and DMAsIII
have been detected in urine of individuals
chronically exposed to iAs in drinking water
(5,18–20) and in cultured human hepatic
cells exposed to various concentrations of
iAsIII (18). Studies are currently under way
in several laboratories to elucidate the role of
methylated trivalent metabolites in the sys-
temic toxicity and carcinogenicity of iAs.
This report summarizes some recent work
linking the metabolism of arsenic to its
biological effects.
Toxicity of Methylated
Trivalent Arsenicals in
Mammalian Cells
Cytotoxic effects of trivalent and pentavalent
arsenicals have previously been examined in
several cell types, including primary human
hepatocytes, primary human bronchial epithe-
lial cells (HBEC), NHEK), SV-40–immortal-
ized human bladder epithelial (UROtsa) cells,
HeLa cells (12,13), and Chang liver cells (14).
Pentavalent arsenicals were significantly less
cytotoxic than their trivalent counterparts
(12–14). Among trivalent arsenicals, MAsIIIO
and MAsIIII2 were the most cytotoxic species,
followed by DMAsIIII, DMAsIIIGS, and iAsIII.
We have recently examined cytotoxicity of
arsenicals in several other mammalian cell
types, including human hepatocellular carci-
noma (HepG2) cells, human bladder transient
carcinoma (T24) cells, human acute promye-
locytic leukemia (NB4) cells, human
monoblastoid (U937) cells, human osteosar-
coma (HOS) cells, human neuroblastoma
(SK-N-SH) cells, mouse 3T3 adipocytes, pri-
mary guinea pig hepatocytes, and Chinese
hamster lung (V79-4) cells (Table 1).
Regardless of the cell type, trivalent
monomethylated arsenicals, MAsIIIO and
MAsIIII2, were the most potent cytotoxins,
with LC50 values ranging from 0.4 to 5.5 µM.
DMAsIII derivatives were as cytotoxic as
MAsIII species and more cytotoxic than iAsIII
in most cell types.
The thiazolyl blue (MTT) assay that moni-
tors the activity of mitochondrial dehydroge-
nases in viable cells has been used to examine
cytotoxicity of arsenicals in all these cell types.
The neutral red assay that measures the uptake
of the die by viable cells has also been used in
some experiments. Because the cell viability
values determined by the neutral red assay
were lower that those obtained by the MTT
This article is part of the monograph Molecular
Mechanisms of Metal Toxicity and Carcinogenicity.
Address correspondence to M. Sty ´blo, Dept. of
Pediatrics, CB# 7220, Burnett-Womack Clinical
Sciences Bldg., University of North Carolina,
Chapel Hill, NC 27599-7220 USA. Telephone:
(919) 966-5721. Fax: (919) 966-0135. E-mail:
styblo@med.unc.edu
Research in the laboratory of M.S. has been
supported by Drinking Water STAR grant
R826136-01-0 from the U.S. Environmental
Protection Agency, National Institutes of Health
(NIH) grant ES09941, and NIH Clinical Nutrition
Research Center grant DK 56350. We thank
W. Cullen for synthesis of methylated trivalent
arsenicals and N. Unimye, S. Waxman, T. Rossman,
Y. Patel, J. Blatt, M. Mass, and A. Klingerman for
providing cell lines used for this research. The man-
uscript was reviewed in accordance with the policy
of the Health Effects Research Laboratory, U.S.
Environmental Protection Agency, and approved for
publication. Approval does not signify that the con-
tents necessarily reﬂect the views and policies of the
agency, nor does mention of trade names or
commercial products constitute endorsement or
recommendation for use.
Received 13 February 2002; accepted 31 May 2002.
Metals Toxicity
Recent research of the metabolism and biological effects of arsenic has profoundly changed our
understanding of the role of metabolism in modulation of toxicity and carcinogenicity of this met-
alloid. Historically, the enzymatic conversion of inorganic arsenic to mono- and dimethylated
species has been considered a major mechanism for detoxiﬁcation of inorganic arsenic. However,
compelling experimental evidence obtained from several laboratories suggests that biomethylation,
particularly the production of methylated metabolites that contain trivalent arsenic, is a process
that activates arsenic as a toxin and a carcinogen. This article summarizes this evidence and pro-
vides new data on a) the toxicity of methylated trivalent arsenicals in mammalian cells, b) the
effects of methylated trivalent arsenicals on gene transcription, and c) the mechanisms involved in
arsenic methylation in animal and human tissues. Key words: AP-1, arsenic, cancer, inhibition,
methylated arsenic, methylation, methyltransferase, toxicity, transcription control. Environ Health
Perspect 110(suppl 5):767–771 (2002).
http://ehpnet1.niehs.nih.gov/docs/2002/suppl-5/767-771styblo/abstract.html
The Role of Biomethylation in Toxicity and Carcinogenicity of
Arsenic: 
A Research Update
Miroslav Sty ’blo,1,2,3 Zuzana Drobná,1 Ilona Jaspers,1,3 Shan Lin,4 and David J. Thomas5
1Department of Pediatrics, 2Department of Nutrition, 3Center for Environmental Medicine and Lung Biology, and 4Curriculum in
Toxicology, University of North Carolina, Chapel Hill, North Carolina, USA; 5Pharmacokinetics Branch, Experimental Toxicology768 VOLUME 110 | SUPPLEMENT 5 | OCTOBER 2002 • Environmental Health Perspectives
assay (12,15), it is possible that the latter assay
underestimates cytotoxic effects of arsenicals in
cultured cells. Figure 2 shows an example of
the concentration-dependent effects of trival-
ent arsenicals on cell viability in human
leukemia NB4 and U937 cell lines. Increased
cell viability values found after 24-hr exposures
to low concentrations of arsenicals were associ-
ated with increased cell proliferation rates. The
induction of cell proliferation by low concen-
trations of trivalent arsenicals has previously
been reported in several cell types [e.g., NHEK
(15)]. Notably, among cell types examined,
NB4 cells were most sensitive to cytotoxic
effects of trivalent arsenicals.
As shown in Table 1, there was no
apparent correlation between the capacity of
cells to methylate iAs and their sensitivity to
the cytotoxic effects of trivalent arsenicals,
indicating that the capacity to methylate has
little to do with the resistance of cells to acute
toxicity of AsIII. In some cases, iAsIII was
more toxic in cells with a high methylation
capacity (e.g., rat hepatocytes) than in cells
that do not methylate this arsenical (e.g.,
guinea pig hepatocytes). Consequently,
mechanisms other than methylation (e.g.,
transport of arsenicals across the cell mem-
brane or protein binding) may play a critical
role in the detoxification of trivalent arseni-
cals under acute exposure conditions. These
results suggest that production and accumula-
tion of MAsIII and/or DMAsIII, the most
cytotoxic species among biologically relevant
arsenicals, may be directly linked to adverse
effects associated with in vivo exposures to
iAs. We have previously shown that HepG2
cells exposed to iAsIII produced both MAsIII
and DMAsIII. In addition, both MAsIII and
DMAsIII synthesized in HepG2 cells were
released into culture medium (18). Hence,
MAsIII and DMAsIII may be translocated
from methylating cells to tissues and cells that
cannot methylate iAs. Notably, production of
MAsIII and DMAsIII by HepG2 cells
increased with increasing concentrations of
iAsIII in the culture. Similarly, epidemiologic
studies have shown that urinary levels of
MAsIII and DMAsIII in individuals exposed
to iAs in drinking water are positively corre-
lated with exposure levels (5,18). These
results suggest that individuals exposed to
higher levels of iAs may be at greater risk
associated with the production of these toxic
methylated metabolites.
Effects of Methylated
Trivalent Arsenicals on
Gene Transcription
Various hypotheses have been proposed to
explain the carcinogenicity of iAs (28).
Nevertheless, molecular mechanisms by which
this arsenical induces cancer are still poorly
understood. Results of previous studies indi-
cated that iAs does not act through classic
genotoxic and mutagenic mechanisms, but
rather may be a tumor promoter that modiﬁes
signal transduction pathways involved in cell
growth and proliferation (29). iAsIII has been
shown to modulate expression and/or DNA-
binding activities of several key transcription
factors, including nuclear factor kappa B (30),
tumor suppressor 53 (p53) (31), and activat-
ing protein-1 (AP-1) (32–34). Mechanisms of
AP-1 activation by iAsIII include stimulation
of the mitogen-activated protein kinase
(MAPK) cascade with a consequent increase
in the expression and/or phosphorylation of
the two major AP-1 constituents, c-Jun and c-
Fos (29). The modulation of AP-1–dependent
gene transcription by iAsIII may contribute to
the induction of cell proliferation in cultured
cells exposed to this arsenical. However, there
are no data on the effects of methylated triva-
lent arsenicals on AP-1 composition and
DNA-binding activity.
Recently, we have examined c-Jun and
c-Fos expression and AP-1 DNA-binding
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Figure 1. Scheme of the metabolic conversions of
iAs in humans. AdoHcy, S-adenosylhomocysteine;
R, AsV reductase; M, AsIII methyltransferase.
Table 1. Toxicity of trivalent arsenicals in mammalian cells.
Estimated LC50 valuesa (µM) Methylation rateb
Cell type iAsIII MAsIIIO MAsIIII2 DMAsIIIGS DMAsIIII (pmol As/106cells/hr) References
Primary rat
hepatocytes 10– > 20 2.8 1.8 14.5 2.7 19 (12,13)
Primary human 20 5.5 > 20 3.3 (13)
hepatocytes
NHEK 10– > 20 2.6 8.5 0.12 (12,13)
HBEC 3.2 2.7 6.8 0.05 (13)
UROtsa 17.8 2.0 0.8 14.2 > 20 NDc (12,13)
HeLa > 20 2.8 > 20 0.25 (12)
HepG2 > 50 4.0 8.0 0.5 (21)
T24 > 10 2.5 > 10 ND (21)
NB4 1.0 0.4 0.4 ND (22)
U937 5.0 1.0 1.0 ND (22)
HOS 25 1.6 7.0 0.25 (23)
SK-N-SH 40 2.7 2.0 ND (24)
3T3adipocytes 100 5.0 6.0 0.3 (25)
Primary guinea 50 3.2 5.0 ND (26)
pig hepatocytes
V79 4.5 0.5 0.4 ND (27)
Abbreviations: ND, not determined. aLC50 is deﬁned as the concentration of an arsenical that resulted in a 50% decrease
in cell viability over a 24-hr incubation period. The MTT assay was used to examine cell viability in all cell types.
bMethylation rates were determined in cultures exposed to 0.05 or 0.1 µM iAsIII for 24 or 48 hr. cMethylation activity not
detected.
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Figure 2. Effects of trivalent arsenicals on cell viability in (A) NB4 and (B) U937 cultures. Cell viability was
determined by the MTT assay after 24-hr exposures to iAsIII (circles), MAsIIIO (squares), or DMAsIIII (trian-
gles). Each symbol and error bar represents mean and SD for n = 4. Asterisk (*) indicates cell viability in
treated cultures is signiﬁcantly different (p < 0.05) from that in untreated cultures as determined by analysis
of variance with the Dunnett multiple comparison posttest.activity in several human cell lines, including
UROtsa, T24, HepG2, and primary human
hepatocytes exposed to trivalent or pentava-
lent inorganic or methylated arsenicals.
Short-time exposures to trivalent, but not to
pentavalent, arsenicals increased AP-1 DNA-
binding activity in all these cell types. Most
profound effects were found in UROtsa and
T24 cells. In these cell lines, exposures to
MAsIIIO or DMAsIIII signiﬁcantly increased
the levels of nuclear phospho–c-Jun (p-c-Jun)
but had no effects on either c-Jun or c-Fos
levels (35). Importantly, MAsIIIO and
DMAsIIII were considerably more potent
inducers of c-Jun phosphorylation and AP-1
activation than was iAsIII. Neither iAsV nor
methylated pentavalent arsenicals, MAsV or
DMAsV, modified c-Jun phosphorylation.
Figure 3 shows nuclear levels of p-c-Jun in
UROtsa cells exposed for 1 hr to iAsIII,
MAsIIIO, or DMAsIIII (0.5, 1, or 5 µM).
MAsIIIO was the most potent inducer of
p-c-Jun, followed by DMAsIIII. In contrast,
exposures to iAsIII suppressed p-c-Jun levels
in this cell line. The AP-1 DNA-binding
activity was induced in UROtsa cells exposed
to as little as 0.1 µM MAsIIIO (35), a concen-
tration that is well below the LC50 value for
these cells (Table 1).
The potencies of MAsIIIO and DMAsIIII
to stimulate the AP-1–dependent gene
transcription have further been demonstrated
using UROtsa and T24 cells transiently
transfected with an AP-1–dependent
promoter-reporter construct (35). Somewhat
different AP-1 activation patterns were
observed in primary human hepatocytes
(Figure 4). Among trivalent arsenicals exam-
ined, MAsIIIO was the most potent inducer
of c-Jun phosphorylation in these cells.
However, only a weak induction of p-c-Jun
was observed in human hepatocytes exposed
to iAsIII or DMAsIIII. A significant induc-
tion of the AP-1 DNA-binding activity was
detected by the electrophoretic mobility
shift assay (EMSA) only in cells exposed to
5 µM MAsIIIO (Figure 5). Under these
exposure conditions, p-c-Jun, but not c-Fos,
was the major constituent of the AP-1
DNA-binding complex. Based on these
results, the AP-1 DNA-binding activity
appears to be less sensitive to induction by
trivalent arsenicals in primary human hepa-
tocytes than in either UROtsa or T24 cell
lines that are derived from human urinary
bladder. Accordingly, trivalent arsenicals,
particularly MAsIII, are likely to induce the
AP-1–dependent gene transcription in
human bladder to a greater extent than in
the liver. Notably, both hepatic and urinary
bladder cancers have been associated with
chronic exposures to iAs in drinking water.
However, the incidence of bladder cancer
exceeds that of hepatic cancer (36–38).
Thus, trivalent methylated arsenicals that are
chemically consistent with trivalent methy-
lated metabolites of iAs are more potent
than iAs, inducing the DNA-binding activ-
ity of AP-1, a key transcription factor that is
involved in regulation of cell proliferation
and death (29).
Mechanism of iAs
Methylation
The enzymatic reactions involved in the
reduction and methylation of arsenicals have
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Figure 3. Immunoblot analysis of p-c-Jun in nuclear
protein extracts from UROtsa cells exposed to
iAsIII, MAsIIIO, or DMAsIIII for 1 hr and from control
(untreated) cells. Nuclear proteins were separated
by sodium dodecyl sulfate–polyacrylamide gel
electrophoresis and electroblotted on polyvinyl
difluoride membranes. Membranes were blocked
with 5% nonfat milk, washed, and probed with a
mouse monoclonal antibody specific for p-c-Jun
(Santa Cruz Biotechnology, Santa Cruz, CA, USA).
Blots were visualized by an enhanced chemilumi-
nescence technology and quantiﬁed using a digital
imaging system. Immunoblot images (A) and
results of the quantitative analysis of these images
(B) are shown.
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Figure 4. Immunoblot analysis of p-c-Jun in nuclear
protein extracts from primary human hepatocytes
exposed to iAsIII, MAsIIIO, or DMAsIIII for 1 or 2 hr
and from control (untreated) cells. Immunoblot
images (A) and results of the quantitative analysis
of these images (B) are shown. For description of
method, see Figure 3.
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Figure 5. AP-1 DNA-binding activity in primary human hepatocytes treated with trivalent arsenicals and in
control (untreated) cells. (A) EMSA of nuclear protein extracts from cells treated for 1 or 2 hr with iAsIII,
MAsIIIO, or DMAsIIII and from control cells. The DNA–protein binding assay was performed in a reaction
buffer (28) containing a radiolabeled AP-1–binding probe (5´-TGAGTCAG-3´; Promega, Madison, WI, USA),
nuclear proteins, and poly(dI-dC) ⋅ poly(dI-dC) (Boehringer Ingelheim, Ridgeﬁeld, CT, USA). The DNA-bind-
ing complexes were separated by PAGE, and the distribution of radioactivity was analyzed in dried gels by
phosphoimaging. (B) EMSA-supershift analysis of a nuclear protein extract from cells treated with 5 µM
MAsIIII for 1 hr. The reaction and analysis were performed as described for A. To identify the AP-1 dimer
constituents, antibodies specific for p-c-Jun (lane 2) or for c-Fos (lane 3) (both from Santa Cruz
Biotechnology) were added into the DNA–protein binding mixture. The speciﬁcity of the assay was estab-
lished using a 50-fold excess of a wild-type (wt, lane 4) AP-1 probe.been studied in several laboratories using
fractionated tissues, intact cells, and puriﬁed
enzymes (8). Distinct AsV reductases have
been shown to catalyze reduction of iAsV to
iAsIII and of MAsV to MAsIII (4,39). Both
these enzymes require thiols (e.g., GSH) for
reducing activity. The MAsV reductase (Km =
2.6 mM) has recently been identified as
GSH-S-transferase omega (40). Methyl-
transferases that catalyze methylation of iAsIII
and MAsIII have also been identiﬁed. A rab-
bit liver enzyme that converts iAsIII to MAs
and MAsIIIO to DMAs has been puriﬁed and
partially characterized (6). This cytosolic
protein has a molecular weight of about 60
kDa and requires both AdoMet and a thiol
for activity. Consistent with the metabolic
scheme in Figure 1, the puriﬁed enzyme has
a greater afﬁnity for MAsIII than for MAsV.
A novel AsIII methyltransferase (Mr = 41
kDa) has recently been purified by Lin and
co-workers (7) from rat liver. This enzyme
methylates iAsIII in a two-step reaction, in
which MAs is an intermediate and DMAs is
the ﬁnal product. The two-step kinetics of this
reaction is consistent with kinetic patterns of
iAsIII methylation reported in in vitro studies
using tissue extracts (41,42). AdoMet is the
essential methyl group donor for both methyl-
ation steps (Table 2). MAsIIIO is also a sub-
strate for this enzyme in a methylation
reaction yielding DMAs. A kinetic analysis of
this reaction showed a low Km of 250 nM
MAsIIIO. Thus, this enzyme can effectively
methylate at very low concentrations of
MAsIII in tissues. However, high concentra-
tions of MAsIIIO (≥5 µM) inhibit DMAs syn-
thesis. The rat AsIII methyltransferase requires
a dithiol for its activity. Dithiothreitol (DTT)
has been used as an enzyme co-factor in in
vitro assays with puriﬁed rat AsIII methyltrans-
ferase. Protein and cDNA sequences for the
rat AsIII methyltransferase have been obtained.
Sequence analyses have revealed a high degree
of homology with a putative human methyl-
transferase CYT19, indicating that CYT19 is
the human AsIII methyltransferase. Using
reverse-transcription polymerase chain reac-
tion, mRNA for AsIII methyltransferase has
been detected in rat tissues (liver, heart, lung,
kidney, adrenal, bladder, and brain) and also
in human hepatoma (HepG2) cells that are
known to methylate iAsIII (18). In contrast,
mRNA for this enzyme has not been found in
UROtsa cells, human urinary bladder cells
that do not produce methylated metabolites
when exposed to iAsIII in culture (12,13).
Based on results of the in vitro studies, the
presence of a dithiol is an essential requirement
for the rat AsIII methyltransferase activity.
Thioredoxin (TRx), a small (12 kDa) protein
with a pair of redox-active cysteine residues
(44), is a likely candidate for the role of a
cofactor for this enzyme in mammalian cells.
In fact, TRx and DTT are equally effective in
supporting the in vitro AsIII methyltransferase
activity (43). The main function of TRx in
cells is the reduction of disulﬁde bonds in mol-
ecules of various proteins, including enzymes,
cellular receptors, and transcription factors.
During this reaction, the redox-active
sulfhydryl groups in TRx molecule are oxi-
dized to form a disulfide (45). The oxidized
TRx is then reactivated in an NADPH-depen-
dent reaction catalyzed by TRx-reductase
(TR) (44).
The mechanism of interactions between
TRx and AsIII methyltransferase has not been
examined. It is likely that TRx is involved in
the reduction of the pentavalent intermediate,
MAsV. TRx may directly reduce MAsV to
MAsIII before the second methylation step. It
may also be a donor of electrons for reduction
(reactivation) of redox-active cysteinyl residues
of the AsIII methyltransferase that are respon-
sible for MAsV reduction. Alternatively, TRx
may reduce other cysteinyl residues that are
required for the catalytically active conforma-
tion of the enzyme. Notably, interactions
between TRx and AsIII methyltransferase pro-
vide a basis for a hypothetical mechanism that
may play an important role in the regulation
of this enzyme (Figure 6). It has been shown
that MAsIII derivatives [MAsIIIO or MAsIIII2]
are potent inhibitors of TR (11), the enzyme
responsible for TRx reactivation. In cell cul-
tures exposed to iAsIII, inhibition of TR activ-
ity correlates with accumulation of MAs in
cells (46). These data suggest that MAsIII, the
intermediate formed in the course iAs methy-
lation, is responsible for inhibition of TR
activity. The inhibition of TR by MAsIII may
result in a decreased availability of the active
(reduced) form of TRx in cells, preventing
further reduction of MAsV to MAsIII. This
hypothetical regulatory mechanism would
retard the formation of MAsIII when the con-
centrations of this toxic intermediate in cells
reached low micromolar values.
Conclusions
The results of previous studies and new
experimental data presented here suggest
that exposures to methylated trivalent
arsenicals are associated with a variety of
adverse effects that have a profound impact
on cell viability or proliferation. The known
effects include a) inhibition of several key
enzymes, b) damage to DNA structure, and
c) activation of AP-1–dependent gene tran-
scription. Notably, trivalent methylated
arsenicals, MAsIII and/or DMAsIII deriva-
tives, are more potent than iAsIII in produc-
ing these effects. These findings are
consistent with the concept of biomethyla-
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Table 2. Properties of AsIII methyltransferase from rat liver.a
Molecular mass 42,000 Da (determined by PAGE); 41,056 Da (calculated)
Primary structure 369 amino acid residues; cysteine-rich protein (12 cysteine residues); common
characteristics methyltransferase motifs, including the AdoMet binding motifs
Kinetic characteristics Km = 250 nM, Vmax = 68 pmol/mg protein/min [with MAsIIIO as a substrate]; pH optimum = 
9.5 (active from pH 7 to 11)
Essential co-factors Dithiol (e.g., DTT, TRx); AdoMet (the methyl group donor)
Known inhibitor MAsIIIO (≥ 5 µM) inhibits DMAs formation in the second methylation reaction
aData from Lin et al. (7) and Lin and Thomas (43).
Figure 6. Hypothetical mechanism of the methylation of iAs by AsIII methyltransferase: the role of Trx and
TR. AsV-R, AsV reductase; AsIII-MT, AsIII methyltransferase.tion being a process that potentiates toxicity
and carcinogenicity of iAs.
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